257 related articles for article (PubMed ID: 15095753)
1. The CHARM programme raises the profile of candesartan cilexetil in the treatment of chronic health failure.
Cardiovasc J S Afr; 2004; 15(1):42-3. PubMed ID: 15095753
[No Abstract] [Full Text] [Related]
2. CHARM study in CHF patients with impaired LV function reinforces benefits of candesartan cilexetil (Atacand).
Cardiovasc J S Afr; 2004; 15(5):252. PubMed ID: 15483738
[No Abstract] [Full Text] [Related]
3. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
4. [CHARM study--new strategy for the treatment of heart failure].
Hasegawa H; Komuro I
Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833
[TBL] [Abstract][Full Text] [Related]
5. Exploring new treatment strategies in heart failure.
Swedberg K
Blood Press Suppl; 2000; 1():44-8. PubMed ID: 11059637
[TBL] [Abstract][Full Text] [Related]
6. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
McKelvie RS
J Hypertens Suppl; 2006 Mar; 24(1):S9-13. PubMed ID: 16601580
[TBL] [Abstract][Full Text] [Related]
7. Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.
Plosker GL; Keam SJ
Pharmacoeconomics; 2006; 24(12):1249-72. PubMed ID: 17129078
[TBL] [Abstract][Full Text] [Related]
8. CHARM shows improvement in NYHA functional class with candesartan.
Cardiovasc J S Afr; 2004; 15(2):96-7. PubMed ID: 15148548
[No Abstract] [Full Text] [Related]
9. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
Rakugi H; Ogihara T
Nihon Rinsho; 2001 Oct; 59(10):2051-61. PubMed ID: 11676153
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial.
Bhakta S; Dunlap ME
Cleve Clin J Med; 2004 Aug; 71(8):665-73. PubMed ID: 15449762
[TBL] [Abstract][Full Text] [Related]
11. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.
Swedberg K; Pfeffer M; Granger C; Held P; McMurray J; Ohlin G; Olofsson B; Ostergren J; Yusuf S
J Card Fail; 1999 Sep; 5(3):276-82. PubMed ID: 10496201
[TBL] [Abstract][Full Text] [Related]
12. [AT1 blockers against heart failure. The charm of polypharmacy].
MMW Fortschr Med; 2003 Sep; 145(38):6. PubMed ID: 14603670
[No Abstract] [Full Text] [Related]
13. Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
Swedberg K; McMurray JJ
Eur Heart J; 2004 Mar; 25(5):357-8. PubMed ID: 15033244
[No Abstract] [Full Text] [Related]
14. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Baumgart P; Reismann J; Pohlmeyer H; Düsing R
Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
[TBL] [Abstract][Full Text] [Related]
15. Candesartan cilexetil: an update.
Joost A; Schunkert H; Radke PW
Expert Opin Pharmacother; 2011 Aug; 12(11):1769-80. PubMed ID: 21651457
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
Franke H
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S61-2. PubMed ID: 9331010
[No Abstract] [Full Text] [Related]
17. Candesartan and heart failure: the allure of CHARM.
White HD
Lancet; 2003 Sep; 362(9386):754-5. PubMed ID: 13678864
[No Abstract] [Full Text] [Related]
18. [CHARM].
Momomura S
Nihon Rinsho; 2006 Aug; 64 Suppl 6():431-6. PubMed ID: 16981575
[No Abstract] [Full Text] [Related]
19. The CHARM programme.
Penston J
Lancet; 2003 Nov; 362(9396):1678; author reply 1678-9. PubMed ID: 14630459
[No Abstract] [Full Text] [Related]
20. The CHARM programme.
Mansour J; Peltier M; Oprisiu R; Achard JM; Fournier A
Lancet; 2003 Nov; 362(9396):1676-7; author reply 1678-9. PubMed ID: 14630455
[No Abstract] [Full Text] [Related]
[Next] [New Search]
